Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545762 | 0.76 | THRA (0.41) | MAPK9MAPK10MEN1KMT2ABCL2 | |
| SCHEMBL5016505 | 0.73 | MAPK9 (0.37) | MAPK9MAPK10MEN1KMT2ABCL2 | |
| SCHEMBL11928842 | 0.69 | CA2 (0.37) | MAPK9MAPK10MEN1KMT2ABCL2 | |
| SCHEMBL3541193 | 0.69 | LSS (0.45) | MEN1KMT2ACXCR3 | |
| SCHEMBL924672 | 0.69 | MAPK9 (0.49) | MAPK9MAPK10MEN1KMT2ABCL2 | |
| SCHEMBL5016503 | 0.69 | MAPK9 (0.39) | MAPK9MAPK10MEN1KMT2ABCL2 | |
| SCHEMBL3545422 | 0.68 | CA2 (0.41) | MAPK9MAPK10MEN1KMT2ABCL2 | |
| SCHEMBL13998433 | 0.68 | MAPK9 (0.48) | MAPK9MAPK10MEN1KMT2ABCL2 | |
| SCHEMBL6021534 | 0.67 | DDR1 (0.41) | MAPK9MAPK10MEN1KMT2ABCL2 | |
| SCHEMBL3540537 | 0.67 | KMT2A (0.47) | MAPK9MAPK10MEN1KMT2ABCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | disclosed |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1409483-B1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | SERONO LAB (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MERCK SERONO SA (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1409483-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010164-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MAPK1, MAPK3, MAP3K2 | MAPK9 28/4885MAPK10 49/4885MEN1 3849/4885 |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | MAPK1, MAPK3, MAP3K2 | MAPK9 29/4885MAPK10 44/4885MEN1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.